Posts By :

Michael

Lysogene Announces Favorable DSMB Review Recommending Study Continuation and Positive Biomarker Data in Stage 1 of Adaptative Clinical Trial with LYS-GM101 Gene Therapy in GM1 Gangliosidosis
Lysogene Announces Favorable DSMB Review Recommending Study Continuation and Positive Biomarker Data in Stage 1 of Adaptative Clinical Trial with LYS-GM101 Gene Therapy in GM1 Gangliosidosis 150 150 Lysogene

Completion of treatment and 6 months follow-up for the last patient enrolled in Stage 1…

Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study
Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study 150 150 Lysogene

In the cohort of patients enrolled before the age of 30 months, a statistically significant…

Lysogene to Provide Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday, November 23, 2022
Lysogene to Provide Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday, November 23, 2022 150 150 Lysogene

Live webcast to be hosted on Wednesday, November 23, 2022 at 1:30 pm CET Paris,…

Lysogene Reports its Cash Position as of 30 September 2022
Lysogene Reports its Cash Position as of 30 September 2022 150 150 Lysogene

Cash and cash equivalents of €6.1 million[1] as of 30 September 2022 Paris, France —…

Lysogene Reports First Half 2022 Financial Results
Lysogene Reports First Half 2022 Financial Results 150 150 Lysogene

Full data analysis of AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in MPS…

Lysogene: New Board of Directors
Lysogene: New Board of Directors 150 150 Lysogene

Paris, France —16 September 2022 at 8:00 am CET — Lysogene (FR0013233475 – LYS), a…

Lysogene Reports its Cash Position as of 30 June 2022
Lysogene Reports its Cash Position as of 30 June 2022 150 150 Lysogene

Cash and cash equivalents of €7.7 million[1] as of 30 June 2022 Paris, France —…

Half-year liquidity contract statement for LYSOGENE
Half-year liquidity contract statement for LYSOGENE 150 150 Lysogene

  Paris, France —11 July 2022 at 06:00 pm — Lysogene (FR0013233475 – LYS) —…

Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA
Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA 150 150 Lysogene

• Positive biomarker data confirmed in additional subjects and at additional timepoints • Stable or…

Lysogene releases results from June 24,2022, ordinary and extraordinary annual general meeting. Shareholders approved all proposed resolutions.
Lysogene releases results from June 24,2022, ordinary and extraordinary annual general meeting. Shareholders approved all proposed resolutions. 150 150 Lysogene

  Paris, France —27 June 2022 at 8:00 am CET — Lysogene (FR0013233475 – LYS),…

  • 1
  • 2

Lysogene COVID-19 update

Find out More

Lysogene is developing therapies for children with CNS diseases.

Delivering Gene Therapy’s Promise

About Us
Our Science
Meet the Team
Diseases
Resources

Contact Us
Careers
Transparency
Compassionate Use Policy

©2022 Lysogene. All rights reserved.

Cookie Policy
Privacy Policy
Legal Notice

Get In Touch

Don’t hesitate to contact us if you need more help.

    Start Typing